Proteomic profiling of a patient with cutaneous melanoma metastasis regression following topical contact sensitizer diphencyprone and immune checkpoint inhibitor treatment

HIGHLIGHTS

• who: Joseph Han from the DepartmentUniversity of have published the research work: Proteomic profiling of a patient with cutaneous melanoma metastasis regression following topical contact sensitizer diphencyprone and immune checkpoint inhibitor treatment, in the Journal: Scientific Reports Scientific Reports

SUMMARY

DPCP and pembrolizumab have contrasting effects on immune checkpoint protein levels in tissue when used as monotherapy. Within the tissue samples, protein levels of checkpoint inhibitor proteins PD-1, PD-L1, and lymphocyte-activation gene 3 (LAG-3) rose from baseline until the discontinuation of DPCP monotherapy at Day 80 by 22.7 . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.